{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:08:13Z","timestamp":1792098493437,"version":"4.4.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T00:00:00Z","timestamp":1482192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A15601"],"award-info":[{"award-number":["A15601"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A11906"],"award-info":[{"award-number":["A11906"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A20240"],"award-info":[{"award-number":["A20240"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A18072"],"award-info":[{"award-number":["A18072"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arthritis Research UK (GB)"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002198","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T13:29:11Z","timestamp":1482240551000},"page":"e1002198","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":283,"title":["Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study"],"prefix":"10.1371","volume":"13","author":[{"given":"Christine A.","family":"Parkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davina","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Piskorz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Biggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-1740","authenticated-orcid":false,"given":"Charlotte","family":"Hodgkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Addley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Moyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evis","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hosking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Gounaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-5462","authenticated-orcid":true,"given":"Mercedes","family":"Jimenez-Linan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-3471","authenticated-orcid":true,"given":"Wendi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitzan","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Brenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,12,20]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid biopsy: monitoring cancer-genetics in the blood","volume":"10","author":"E Crowley","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1021\/pr050027n","article-title":"Perspective: a program to improve protein biomarker discovery for cancer","volume":"4","author":"R Aebersold","year":"2005","journal-title":"J Proteome Res"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"I Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"CM Sturgeon","year":"2008","journal-title":"Clin Chem"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers","volume":"26","author":"G Soletormos","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"22","key":"ref6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"SS Buys","year":"2011","journal-title":"JAMA"},{"issue":"10022","key":"ref7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"IJ Jacobs","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1525-1438.2002.01171.x","article-title":"The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma","volume":"12","author":"U Saygili","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1757-2215-2-13","article-title":"Role of CA125 in predicting ovarian cancer survival\u2014a review of the epidemiological literature","volume":"2","author":"D Gupta","year":"2009","journal-title":"J Ovarian Res"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.05.001","article-title":"Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer","volume":"69","author":"A Gadducci","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"ref11","first-page":"3254","article-title":"Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma","volume":"9","author":"EW To","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"F Diehl","year":"2008","journal-title":"Nat Med"},{"issue":"1","key":"ref13","first-page":"67","article-title":"Soluble normal and mutated DNA sequences from single-copy genes in human blood","volume":"3","author":"GD Sorenson","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2141.1994.tb04828.x","article-title":"Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia","volume":"86","author":"V Vasioukhin","year":"1994","journal-title":"Br J Haematol"},{"issue":"224","key":"ref15","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"C Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"SJ Dawson","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"AM Newman","year":"2014","journal-title":"Nat Med"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/1078-0432.CCR-08-2622","article-title":"Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients","volume":"15","author":"TK Yung","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"LA Diaz Jr","year":"2014","journal-title":"J Clin Oncol"},{"issue":"45","key":"ref20","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"F Diehl","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"136","key":"ref21","doi-asserted-by":"crossref","first-page":"136ra68","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"T Forshew","year":"2012","journal-title":"Sci Transl Med"},{"issue":"8","key":"ref22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","article-title":"Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer","volume":"26","author":"J Tie","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"AA Ahmed","year":"2010","journal-title":"J Pathol"},{"issue":"7353","key":"ref24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma","volume":"2","author":"M K\u00f6bel","year":"2016","journal-title":"J Pathol Clin Res"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"RC Bast Jr","year":"1981","journal-title":"J Clin Invest"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2009.09.041","article-title":"Current state of biomarker development for clinical application in epithelial ovarian cancer","volume":"116","author":"RG Moore","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ajog.2005.01.054","article-title":"Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer","volume":"193","author":"EM Swisher","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1048-891x.2004.014305.x","article-title":"Detection of p53 mutations in the plasma DNA of patients with ovarian cancer","volume":"14","author":"J Otsuka","year":"2004","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"e0145754","DOI":"10.1371\/journal.pone.0145754","article-title":"Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers","volume":"10","author":"E Pereira","year":"2015","journal-title":"PLoS ONE"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"E von Elm","year":"2007","journal-title":"PLoS Med"},{"issue":"16","key":"ref32","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"LM McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5797","key":"ref34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The consensus coding sequences of human breast and colorectal cancers","volume":"314","author":"T Sjoblom","year":"2006","journal-title":"Science"},{"issue":"48","key":"ref35","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1038\/onc.2011.653","article-title":"Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium","volume":"31","author":"KM Archibald","year":"2012","journal-title":"Oncogene"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"GJ Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"ref37","first-page":"3467","article-title":"Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer","volume":"32","author":"JH No","year":"2012","journal-title":"Anticancer Res"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1183\/13993003.00676-2015","article-title":"Circulating free DNA concentration is an independent prognostic biomarker in lung cancer","volume":"46","author":"C Tissot","year":"2015","journal-title":"Eur Respir J"},{"key":"ref39","year":"2016"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1158\/1078-0432.CCR-13-2634","article-title":"Repeatability of quantitative FDG-PET\/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume","volume":"20","author":"AG Rockall","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ref41","first-page":"1903","article-title":"Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer","volume":"22","author":"E Andreopoulou","year":"2002","journal-title":"Anticancer Res"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients","volume":"8","author":"EA Eisenhauer","year":"1997","journal-title":"Ann Oncol"},{"issue":"2","key":"ref43","first-page":"88","article-title":"Prognostic value of (18)F-FDG PET\/CT volumetric parameters in recurrent epithelial ovarian cancer","volume":"35","author":"M Mayoral","year":"2016","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1007\/s00330-015-3729-9","article-title":"Volume-based quantitative FDG PET\/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery","volume":"25","author":"HA Vargas","year":"2015","journal-title":"Eur Radiol"},{"issue":"5","key":"ref45","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm","volume":"104","author":"T Van Gorp","year":"2011","journal-title":"Br J Cancer"},{"issue":"4","key":"ref46","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"G Blackledge","year":"1989","journal-title":"Br J Cancer"},{"issue":"3","key":"ref47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"M Markman","year":"1991","journal-title":"J Clin Oncol"},{"issue":"15","key":"ref48","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"M Markman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/annonc\/mds538","article-title":"A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer","volume":"24","author":"CK Lee","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ygyno.2015.09.011","article-title":"Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer","volume":"139","author":"KH Eng","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"17","key":"ref51","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/jnci\/djr282","article-title":"Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer","volume":"103","author":"CK Lee","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"ref52","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2014.04.003","article-title":"Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development","volume":"133","author":"M Wilbaux","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"3","key":"ref53","first-page":"269","article-title":"Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers","volume":"33","author":"T Yoshikawa","year":"2012","journal-title":"Eur J Gynaecol Oncol"},{"issue":"14","key":"ref54","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1093\/nar\/gkv111","article-title":"TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer","volume":"43","author":"J Chien","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"ref55","doi-asserted-by":"crossref","first-page":"e1001789","DOI":"10.1371\/journal.pmed.1001789","article-title":"Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis","volume":"12","author":"RF Schwarz","year":"2015","journal-title":"PLoS Med"},{"issue":"5","key":"ref56","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdw037","article-title":"Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer","volume":"27","author":"M Jamal-Hanjani","year":"2016","journal-title":"Ann Oncol"},{"issue":"6206","key":"ref57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1126\/science.1253462","article-title":"Spatial and temporal diversity in genomic instability processes defines lung cancer evolution","volume":"346","author":"EC de Bruin","year":"2014","journal-title":"Science"},{"issue":"31","key":"ref58","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","article-title":"Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500","volume":"32","author":"JB Smerage","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/bjc.2015.278","article-title":"A Bayesian adaptive design for biomarker trials with linked treatments","volume":"113","author":"JM Wason","year":"2015","journal-title":"Br J Cancer"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:55:04Z","timestamp":1589702104000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002198"}},"subtitle":[],"editor":[{"given":"Elaine Rene","family":"Mardis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,20]]},"references-count":59,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002198","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,20]]}}}